Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Current Clinical Application of the CAR-T Cell Therapy

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

A long way to the battlefront: CAR T cell therapy against solid cancers.

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Current Progress in Chimeric Antigen Receptor T‐cell Therapy for Malignant Tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors